The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Opdivo (nivolumab) as a monotherapy for the adjuvant treatment of adults and adolescents 12 years of age and older with completely resected stage 2B or 2C melanoma.
2023
Ground-breaking vaccine preventing melanoma | 7NEWS
A new weapon in the fight against skin cancer could soon be available in Australia. The groundbreaking vaccine prevents melanoma from recurring in patients. Potentially life-saving testing is underway – there is even talk of a cure.
Vitamin D Maintenance Should Be ‘Standard’ for Advanced Melanoma
A recent study documented the benefits of maintaining normal vitamin D levels for patients with inoperable, locally advanced or metastatic melanoma receiving anti-PD-1 immunotherapy.
Dr Buchbinder on Treatment Decisions After Severe irAEs With Nivolumab/Ipilimumab in Melanoma
Elizabeth Buchbinder, MD, assistant professor, Medicine, Harvard Medical School, senior physician, Medical Oncology, Dana-Farber Cancer Institute, discusses the rationale for investigating nivolumab (Opdivo) maintenance therapy in patients with melanoma who experienced severe immune-related adverse effects (irAEs) due to combination therapy with nivolumab and ipilimumab (Yervoy), and details the findings of this investigation.